Go or no go? Aducanumab’s day of reckoning
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Aducanumab tops 2021’s biggest potential launches
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
Some of biopharma’s biggest assets face a solo existence
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Finding the next Vertex
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
Mapping the transatlantic divide for biotech flotations
A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.
The window of opportunity opens wider for Ascendis
With the previous incumbent withdrawn from the market Ascendis hails a new hormone replacement for hypoparathyroidism.
Important catalysts approach for smaller biotechs
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
Will pending clinical readouts make it across the line?
Several key data readouts slated for the first quarter remain unannounced, from Roche, Lilly, Axsome and others, but the Covid-19 pandemic puts many at risk of delay.
